Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.42 |
| ▸ | AR | P10275 | 4/20 | 0.42 |
| ▸ | VDR | P11473 | 4/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3392768 | 0.98 | ESR1 (0.56) | ESR1ESR2ARVDR | |
| SCHEMBL13366773 | 0.86 | ESR1 (0.51) | ESR1ESR2AR | |
| SCHEMBL3388735 | 0.85 | ESR1 (0.78) | ESR1ESR2ARVDR | |
| SCHEMBL3392770 | 0.83 | ESR1 (0.51) | ESR1ESR2AR | |
| SCHEMBL15076982 | 0.83 | ESR1 (0.51) | ESR1ESR2ARVDR | |
| SCHEMBL3391545 | 0.83 | ESR1 (0.55) | ESR1ESR2ARVDR | |
| SCHEMBL13366769 | 0.82 | ESR1 (0.50) | ESR1ESR2AR | |
| SCHEMBL3391312 | 0.77 | ESR1 (0.49) | ESR1ESR2ARVDR | |
| SCHEMBL3395350 | 0.76 | HDAC6 (0.59) | ESR1ARVDR | |
| SCHEMBL3390952 | 0.76 | ESR1 (0.45) | ESR1ARVDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428447-B2 | Bis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-08-30 | — | — | US | disclosed |
| US-20140315965-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | KALDRE, Dainis (CA) | 2014-10-23 | — | — | US | disclosed |
| EP-2184281-A1 | Phenyl-thiophene type vitamin D receptor modulators | Eli Lilly & Company (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-1511740-B1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1511740-A1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003101978-A1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315965-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | VDR, CYP2R1, CYP24A1 | ESR1 402/4885ESR2 136/4885AR 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.